A Randomized, Single-Blind, Placebo-Controlled, Single-Ascending Dose Crossover Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Orally Administered ARRY-300 in Healthy Subjects.

Trial Profile

A Randomized, Single-Blind, Placebo-Controlled, Single-Ascending Dose Crossover Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Orally Administered ARRY-300 in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Aug 2012

At a glance

  • Drugs ARRY 300 (Primary)
  • Indications Cancer; Inflammation
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics
  • Sponsors Array BioPharma
  • Most Recent Events

    • 25 Apr 2009 Actual initiation date (Jan 2009) added as reported by ClinicalTrials.gov.
    • 25 Apr 2009 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
    • 25 Apr 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top